Brokerages Set Immunic, Inc. (NASDAQ:IMUX) Target Price at $7.40

Immunic, Inc. (NASDAQ:IMUX) has been assigned a consensus recommendation of “Buy” from the nine analysts that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, five have issued a buy rating and three have assigned a strong buy rating to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $7.40.

Several analysts have issued reports on the stock. Roth Mkm began coverage on shares of Immunic in a research note on Friday, November 7th. They issued a “buy” rating and a $3.00 target price on the stock. Brookline Capital Management upgraded shares of Immunic to a “strong-buy” rating in a research report on Tuesday. HC Wainwright decreased their price target on shares of Immunic from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Friday, November 14th. D. Boral Capital restated a “buy” rating and set a $8.00 price objective on shares of Immunic in a research report on Wednesday, January 7th. Finally, LADENBURG THALM/SH SH raised shares of Immunic to a “strong-buy” rating in a report on Thursday, October 16th.

Immunic Stock Down 5.0%

IMUX opened at $0.59 on Friday. Immunic has a twelve month low of $0.51 and a twelve month high of $1.39. The firm has a 50-day moving average price of $0.63 and a 200-day moving average price of $0.77. The company has a market capitalization of $70.85 million, a price-to-earnings ratio of -0.71 and a beta of 1.58.

Immunic (NASDAQ:IMUX) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.05. On average, sell-side analysts expect that Immunic will post -0.94 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Immunic

A number of hedge funds and other institutional investors have recently modified their holdings of IMUX. Aberdeen Group plc boosted its stake in shares of Immunic by 678.1% during the second quarter. Aberdeen Group plc now owns 8,243,941 shares of the company’s stock valued at $5,750,000 after purchasing an additional 7,184,457 shares during the period. Millennium Management LLC raised its holdings in Immunic by 414.5% during the 3rd quarter. Millennium Management LLC now owns 530,470 shares of the company’s stock valued at $468,000 after buying an additional 427,361 shares during the last quarter. Squarepoint Ops LLC purchased a new stake in Immunic during the 3rd quarter valued at $239,000. Vanguard Group Inc. grew its holdings in Immunic by 5.3% in the 3rd quarter. Vanguard Group Inc. now owns 4,345,105 shares of the company’s stock worth $3,832,000 after acquiring an additional 219,957 shares during the last quarter. Finally, GSA Capital Partners LLP bought a new stake in Immunic in the 3rd quarter worth $170,000. 51.82% of the stock is currently owned by hedge funds and other institutional investors.

About Immunic

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.